CSF-1/CSF-1R blockade promotes antitumor T cell responses and reduces tumor growth in several preclinical models in combination with immunotherapy, despite showing minor effects on tumor growth as a monotherapy (81, 86, 183, 184). The gene discussed is CSF1R; the disease is neoplasm.